Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H FLEISCH

Showing results (211-220 of 212) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 212 results.
The Journal of Pharmacology and Experimental Therapeutics|February 23, 1999
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPID W Snyder, N J Bach, R D Dillard, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 23, 1998
Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studiesW T Jackson, L L Froelich, R J Boyd, et al.
Pageof 22

Showing results (211-220 of 212) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 212 results.
The Journal of Pharmacology and Experimental Therapeutics|February 23, 1999
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPID W Snyder, N J Bach, R D Dillard, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 23, 1998
Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studiesW T Jackson, L L Froelich, R J Boyd, et al.
Pageof 22